Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Metformin – Forschungsarchiv – Seite 31 von 35 | SupStack

Metformin – Forschungsarchiv

Studien 2451–2500 von 2685, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

2451RCT2004

Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH · Eur J Pharm Sci (2004)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Metformin – Forschungsarchiv

Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet.

Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.

Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers.

Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.

Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study.

Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes.

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.

A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome.

[Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.

Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients.

Effect of metformin on insulin sensitivity and insulin secretion in female obese patients with normal glucose tolerance.

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

Metformin blunts stress-induced hyperglycemia after thermal injury.

Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus.

Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure.

The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a controlled, randomized, double-blind, crossover study.

The diabetes prevention program and its global implications.

Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome.

Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients.

Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.

Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.

Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome.

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.

Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes.

[Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome].

Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen.

Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study.

Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.

Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.

Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.

Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.

Crossover and double blind study with metformin and rosiglitazone in impaired glucose tolerance subjects.

Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception.

The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue.

The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial.

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

Contraindications to use of metformin. Metformin may be useful in gestational diabetes.

Comparative bioavailability of two oral formulations manufactured in Mexico containing glyburide and metformin in diabetic patients.

Ondansetron and metformin-induced gastrointestinal side effects.

Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.

Modulation of hunger by plasma glucose and metformin.

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes.

Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.

Genetic cause of hyperglycaemia and response to treatment in diabetes.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis.

Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.

Metformin in polycystic ovary syndrome: systematic review and meta-analysis.